<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858155</url>
  </required_header>
  <id_info>
    <org_study_id>C17 MEL P1</org_study_id>
    <nct_id>NCT01858155</nct_id>
  </id_info>
  <brief_title>Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors</brief_title>
  <official_title>Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C17 Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C17 Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate dose escalation of melatonin in pediatric oncology patients with&#xD;
      relapsed solid tumors. The purpose of this study is to determine the safety of melatonin at a&#xD;
      dose up to 20 mg daily, as well as to determine the maximum tolerated dose of melatonin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated daily dose of melatonin.</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose limiting toxicities during 8 weeks of melatonin therapy.</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of Melatonin.</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The quantity of cytokines will be measured during 8 weeks of melatonin therapy.</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in weight after 8 weeks of therapy.</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Relapsed Malignant Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>SISU Melatonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be able to take medication by mouth either by swallowing, chewing or&#xD;
             sublingual routes.&#xD;
&#xD;
          -  Patients must have a documented life expectancy of ≥ 8 weeks.&#xD;
&#xD;
          -  Patients must have histologic or radiographic evidence of a relapsed malignant solid&#xD;
             tumor. Intrinsic brain stem tumors or optic pathway gliomas may be diagnosed by&#xD;
             clinical and radiologic methods.&#xD;
&#xD;
          -  Patient, parent, legal representative and/or guardian must sign a written informed&#xD;
             consent. Assent, when appropriate, will be obtained according to institutional&#xD;
             guidelines.&#xD;
&#xD;
          -  Minimum Weight Requirements: Dose level 1 - 22.2kg, Dose level 2 - 11.1kg, Dose level&#xD;
             3 - 5.6kg&#xD;
&#xD;
          -  Patients must be taking a stable dose (with no additions, modifications or deletions)&#xD;
             of chemotherapy started ≥ 14 days prior study enrollment.&#xD;
&#xD;
          -  Prescribed Chemotherapy drug(s) must not be known to interact with melatonin&#xD;
&#xD;
          -  Adequate Bone Marrow Function Defined as:&#xD;
&#xD;
               1. Patients with solid tumors without bone marrow involvement:&#xD;
&#xD;
                    -  Peripheral absolute neutrophil count (ANC) ≥ 1 x109/L&#xD;
&#xD;
                    -  Platelet count ≥ 50 X 109/L (transfusion independent, defined as not&#xD;
                       receiving platelet transfusions within a 7 day period prior to enrollment)&#xD;
&#xD;
                    -  Hemoglobin ≥ 80 g/L (may receive RBC transfusions)&#xD;
&#xD;
               2. Patients with known bone marrow metastatic disease are eligible for study but not&#xD;
                  evaluable for hematologic toxicity.&#xD;
&#xD;
                    -  Must not be known to be refractory to red cell or platelet transfusions.&#xD;
&#xD;
                    -  These patients do not need to meet the bone marrow function requirements, as&#xD;
                       hematological toxicity will not be measured due to metastatic disease.&#xD;
&#xD;
          -  Adequate Liver Function Defined as:&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.&#xD;
&#xD;
               -  ALT ≤ 1.5 x ULN for age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy: Melatonin inhibits the action of doxorubicin&#xD;
&#xD;
          -  Growth factors that support white cell number administered ≤ 7 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients requiring corticosteroids who are not on a stable or decreasing dose of&#xD;
             corticosteroid for ≥ 14 days.&#xD;
&#xD;
          -  Patients prescribed immunosuppressant therapy that is not specifically utilized for&#xD;
             chemotherapy purposes. Patient prescribed: Cyclosporine, Mycophenolate Mofetil HCL,&#xD;
             Tacrolimus, Sirolimus and Azathioprine should be excluded&#xD;
&#xD;
          -  Patients prescribed anti-coagulation therapy (Warfarin, Low Molecular Weight Heparin&#xD;
             (LMWH), or System Heparin Therapy)&#xD;
&#xD;
          -  Concomitant medications that are known CYP1A2 inhibitors interact with Melatonin.&#xD;
&#xD;
          -  Patients prescribed megace, corticosteroids and periactin started ≤ 14 days prior to&#xD;
             study enrollment.&#xD;
&#xD;
          -  Patients taking the following medications: benzodiazepines, nifedipine, NSAID's, ASA&#xD;
             and/or Beta Blockers&#xD;
&#xD;
          -  Patients ≤ 7 days post-operative from any surgical procedure.&#xD;
&#xD;
          -  Patients with any signs of active post-operative bleeding.&#xD;
&#xD;
          -  Patients with an infection that is not responding to anti-microbial therapy.&#xD;
&#xD;
          -  Any condition that would negatively impact effective gut absorption and/or swallowing&#xD;
             of study medication.&#xD;
&#xD;
          -  Patients in the opinion of the investigator may not be able to comply with study&#xD;
             protocol requirements&#xD;
&#xD;
          -  Patients already receiving melatonin are excluded from the study.&#xD;
&#xD;
          -  Allergies to the medicinal and/or non-medicinal ingredients of melatonin which&#xD;
             include: Melatonin, Calcium Salicate, Croscarmellose Sodium, IsoMalt, Magnesium&#xD;
             Stearate, Microcrystalline Cellulose.&#xD;
&#xD;
          -  As melatonin can cause fatigue, patients taking melatonin should refrain from driving&#xD;
             or operating machinery within 5 hours of taking the melatonin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Johnston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Eastern Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's &amp; Women's Health Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ste-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

